| Year |
Citation |
Score |
| 2023 |
Torres-Ayuso P, Katerji M, Mehlich D, Lookingbill SA, Sabbasani VR, Liou H, Casillas AL, Chauhan SS, Serwa R, Rubin MR, Marusiak AA, Swenson RE, Warfel NA, Brognard J. PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer. Cell Chemical Biology. PMID 38016478 DOI: 10.1016/j.chembiol.2023.10.023 |
0.468 |
|
| 2022 |
Torres-Ayuso P, Brognard J. Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer. Molecular Pharmacology. 101: 191-200. PMID 35115411 DOI: 10.1124/molpharm.121.000306 |
0.465 |
|
| 2021 |
Torres-Ayuso P, An E, Nyswaner KM, Bensen RC, Ritt DA, Specht SI, Das S, Andresson T, Cachau RE, Liang RJ, Ries AL, Robinson CM, Difilippantonio S, Gouker B, Bassel L, ... ... Brognard J, et al. TNIK is a therapeutic target in Lung Squamous Cell Carcinoma and regulates FAK activation through Merlin. Cancer Discovery. PMID 33495197 DOI: 10.1158/2159-8290.CD-20-0797 |
0.332 |
|
| 2020 |
Hoang VT, Nyswaner K, Torres-Ayuso P, Brognard J. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells. The Journal of Biological Chemistry. PMID 32358059 DOI: 10.1074/Jbc.Ra119.012365 |
0.605 |
|
| 2020 |
Ayuso PT, An E, Ritt D, Nyswaner K, Specht S, Liang R, Das S, Andresson T, Turk B, Morrison D, Brognard J. The protein kinase TNIK: a novel druggable target in Lung Squamous Cell Carcinoma with 3q amplification. The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.03326 |
0.378 |
|
| 2019 |
Torres-Ayuso P, Brognard J. Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. Cancers. 11. PMID 31817861 DOI: 10.3390/Cancers11121972 |
0.592 |
|
| 2019 |
Prelowska M, Mehlich D, Lazniewski M, Kaminska K, Gorczynski A, Korwat A, Sokolowska O, Golab J, Biernat W, Plewczynski D, Brognard J, Nowis D, Marusiak A. Abstract P3-09-07: The role of MLK4 amplification in progression of triple negative breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P3-09-07 |
0.331 |
|
| 2018 |
Marusiak AA, Prelowska MK, Mehlich D, Lazniewski M, Kaminska K, Gorczynski A, Korwat A, Sokolowska O, Kedzierska H, Golab J, Biernat W, Plewczynski D, Brognard J, Nowis D. Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. Oncogene. PMID 30552384 DOI: 10.1038/S41388-018-0618-0 |
0.401 |
|
| 2018 |
An E, Brognard J. Orange is the new black: Kinases are the new master regulators of tumor suppression. Iubmb Life. PMID 30548122 DOI: 10.1002/Iub.1981 |
0.623 |
|
| 2018 |
Torres-Ayuso P, Brognard J. Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors. Cancer Discovery. 8: 1210-1212. PMID 30279193 DOI: 10.1158/2159-8290.Cd-18-0915 |
0.393 |
|
| 2018 |
Torres-Ayuso P, Sahoo S, Ashton G, An E, Simms N, Galvin M, Leong HS, Frese KK, Simpson K, Cook N, Hughes A, Miller CJ, Marais R, Dive C, Krebs MG, ... Brognard J, et al. Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin. Npj Genomic Medicine. 3: 15. PMID 29951225 DOI: 10.1038/S41525-018-0055-6 |
0.499 |
|
| 2018 |
Callender JA, Yang Y, Lordén G, Stephenson NL, Jones AC, Brognard J, Newton AC. Protein kinase Cα gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation. Proceedings of the National Academy of Sciences of the United States of America. PMID 29844158 DOI: 10.1073/Pnas.1805046115 |
0.779 |
|
| 2018 |
Hudson AM, Stephenson NL, Li C, Trotter E, Fletcher AJ, Katona G, Bieniasz-Krzywiec P, Howell M, Wirth C, Furney S, Miller CJ, Brognard J. Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases. Science Signaling. 11. PMID 29666306 DOI: 10.1126/Scisignal.Aan6776 |
0.616 |
|
| 2018 |
Torres-Ayuso P, Sahoo S, Chester C, Hodgkinson C, Galvin M, Leong HS, Frese K, Marais R, Dive C, Krebs M, Brognard J. Abstract A185: Combining unbiased network analysis and cancer genomics to guide precision medicine-oriented early-phase clinical trials Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A185 |
0.443 |
|
| 2017 |
Edwards ZC, Trotter EW, Torres-Ayuso P, Chapman P, Wood HM, Nyswaner K, Brognard J. Survival of head and neck cancer cells relies upon LZK kinase-mediated stabilization of mutant p53. Cancer Research. PMID 28760853 DOI: 10.1158/0008-5472.Can-17-0267 |
0.407 |
|
| 2017 |
Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, ... ... Brognard J, et al. Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. Cancer Cell. 31: 466. PMID 28292443 DOI: 10.1016/J.Ccell.2017.02.007 |
0.336 |
|
| 2017 |
Newton AC, Brognard J. Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. Trends in Pharmacological Sciences. PMID 28283201 DOI: 10.1016/J.Tips.2017.02.002 |
0.734 |
|
| 2017 |
Hudson A, Leong H, Howell M, Trotter E, Papaxoinis G, Miller C, Nonaka D, Brognard J, Mansoor W. 3: Germline sequencing of DIPNECH patients reveals a heterogeneous disease with novel SNVs in genes that are somatically mutated in other neuroendocrine malignancies Lung Cancer. 103: S2. DOI: 10.1016/S0169-5002(17)30053-3 |
0.344 |
|
| 2016 |
Testoni E, Stephenson NL, Torres-Ayuso P, Marusiak AA, Trotter EW, Hudson A, Hodgkinson CL, Morrow CJ, Dive C, Brognard J. Somatically mutated ABL1 is an actionable and essential NSCLC survival gene. Embo Molecular Medicine. PMID 26758680 DOI: 10.15252/Emmm.201505456 |
0.526 |
|
| 2016 |
Torres-Ayuso P, Testoni E, Stephenson NL, Marusiak AA, Trotter EW, Hudson A, Hodgkinson CL, Morrow CJ, Dive C, Brognard J. Abstract 4408: Mutant ABL1 is a genetic dependency in non-small cell lung cancer amenable to pharmacological intervention Cancer Research. 76: 4408-4408. DOI: 10.1158/1538-7445.Am2016-4408 |
0.484 |
|
| 2015 |
Marusiak AA, Stephenson NL, Baik H, Trotter EW, Li Y, Blyth K, Mason S, Chapman P, Puto LA, Read JA, Brassington C, Pollard HK, Phillips C, Green I, Overman R, ... ... Brognard J, et al. Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis. Cancer Research. PMID 26637668 DOI: 10.1158/0008-5472.Can-15-0701-T |
0.644 |
|
| 2015 |
Hudson AM, Wirth C, Stephenson NL, Fawdar S, Brognard J, Miller CJ. Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges. Pharmacogenomics. 1-12. PMID 26230733 DOI: 10.2217/Pgs.15.60 |
0.451 |
|
| 2015 |
Puto LA, Brognard J, Hunter T. Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy. The Journal of Biological Chemistry. 290: 15406-20. PMID 25903140 DOI: 10.1074/Jbc.M115.658765 |
0.415 |
|
| 2015 |
Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, Hunter T, Brognard J, Newton AC. Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell. 160: 489-502. PMID 25619690 DOI: 10.1016/J.Cell.2015.01.001 |
0.753 |
|
| 2015 |
Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BMJM, Menard D, McLeary R, Johnson L, Fish L, ... ... Brognard J, et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma Cancer Cell. 27: 85-96. PMID 25500121 DOI: 10.1016/J.Ccell.2014.11.006 |
0.449 |
|
| 2015 |
Hudson AM, Yates T, Wirth C, Li Y, Trotter W, Fawdar S, Miller C, Brognard J. Abstract A2-18: The challenges of using large-scale genomics data to identify novel drivers of lung cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A2-18 |
0.463 |
|
| 2015 |
Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller C, Furnari F, Hunter T, Brognard J, Newton AC. Abstract 125: Protein kinase C loss-of-function mutations in cancer reveal role as tumor suppressor Cancer Research. 75: 125-125. DOI: 10.1158/1538-7445.Am2015-125 |
0.813 |
|
| 2014 |
Hudson AM, Yates T, Li Y, Trotter EW, Fawdar S, Chapman P, Lorigan P, Biankin A, Miller CJ, Brognard J. Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. Cancer Research. 74: 6390-6. PMID 25256751 DOI: 10.1158/0008-5472.Can-14-1020 |
0.461 |
|
| 2014 |
Reyes G, Niederst M, Cohen-Katsenelson K, Stender JD, Kunkel MT, Chen M, Brognard J, Sierecki E, Gao T, Nowak DG, Trotman LC, Glass CK, Newton AC. Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proceedings of the National Academy of Sciences of the United States of America. 111: E3957-65. PMID 25201979 DOI: 10.1073/Pnas.1404221111 |
0.776 |
|
| 2014 |
Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nature Communications. 5: 3901. PMID 24849047 DOI: 10.1038/Ncomms4901 |
0.472 |
|
| 2014 |
Antal CE, Kang E, Stephenson NL, Trotter EW, Hunter T, Brognard J, Newton A. Abstract 5270: Prevalence of inactivating protein kinase C mutations in human cancers Cancer Research. 74: 5270-5270. DOI: 10.1158/1538-7445.Am2014-5270 |
0.81 |
|
| 2014 |
Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, Mcleary R, Johnson L, Fish L, ... ... Brognard J, et al. Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations Cancer Research. 74: 3704-3704. DOI: 10.1158/1538-7445.Am2014-3704 |
0.435 |
|
| 2014 |
Fawdar S, Trotter EW, Li Y, Miller C, Brognard J. Abstract A10: Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Clinical Cancer Research. 20: A10-A10. DOI: 10.1158/1078-0432.14Aacriaslc-A10 |
0.492 |
|
| 2014 |
Marusiak A, Stephenson N, Baik H, Trotter E, Li Y, Testoni E, Blyth K, Mason S, Puto L, Miller C, Hunter T, Sansom O, Brognard J. 504 Frequent loss-of-function mutations in MLK4 suppresses signaling in the JNK-cJUN-p21/p15 pathway to promote growth of colon cancer cells European Journal of Cancer. 50: 164. DOI: 10.1016/S0959-8049(14)70630-6 |
0.37 |
|
| 2013 |
Fawdar S, Edwards ZC, Brognard J. Druggable drivers of lung cancer. Oncotarget. 4: 1334-5. PMID 23963079 DOI: 10.18632/Oncotarget.1223 |
0.539 |
|
| 2013 |
Fawdar S, Trotter EW, Li Y, Stephenson NL, Hanke F, Marusiak AA, Edwards ZC, Ientile S, Waszkowycz B, Miller CJ, Brognard J. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: 12426-31. PMID 23836671 DOI: 10.1073/Pnas.1305207110 |
0.508 |
|
| 2013 |
Belot A, Kasher PR, Trotter EW, Foray AP, Debaud AL, Rice GI, Szynkiewicz M, Zabot MT, Rouvet I, Bhaskar SS, Daly SB, Dickerson JE, Mayer J, O'Sullivan J, Juillard L, ... ... Brognard J, et al. Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis and Rheumatism. 65: 2161-71. PMID 23666743 DOI: 10.1002/Art.38008 |
0.405 |
|
| 2013 |
Belot A, Kasher P, Trotter E, Foray A, Debaud A, Meffre E, Brognard J, Bonnefoy N, Crow Y. PReS-FINAL-2173: Protein kinase C delta deficiency is a new cause of monogenic SLE Pediatric Rheumatology. 11. DOI: 10.1186/1546-0096-11-S2-O8 |
0.315 |
|
| 2013 |
Fawdar S, Trotter EW, Li Y, Ientile S, Miller C, Brognard J. Abstract 2999: Targeted depletion of all somatically mutated genes in lung cancer cells facilitates identification of mutationally activated novel drivers of lung cancer. Cancer Research. 73: 2999-2999. DOI: 10.1158/1538-7445.Am2013-2999 |
0.456 |
|
| 2011 |
Brognard J, Zhang YW, Puto LA, Hunter T. Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor-suppressing kinase. Cancer Research. 71: 3152-61. PMID 21487036 DOI: 10.1158/0008-5472.Can-10-3543 |
0.634 |
|
| 2011 |
Brognard J, Hunter T. Protein kinase signaling networks in cancer. Current Opinion in Genetics & Development. 21: 4-11. PMID 21123047 DOI: 10.1016/J.Gde.2010.10.012 |
0.581 |
|
| 2009 |
Zhang YW, Brognard J, Coughlin C, You Z, Dolled-Filhart M, Aslanian A, Manning G, Abraham RT, Hunter T. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Molecular Cell. 35: 442-53. PMID 19716789 DOI: 10.1016/J.Molcel.2009.06.030 |
0.47 |
|
| 2009 |
Brognard J, Niederst M, Reyes G, Warfel N, Newton AC. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. The Journal of Biological Chemistry. 284: 15215-23. PMID 19324870 DOI: 10.1074/Jbc.M901468200 |
0.767 |
|
| 2008 |
Brognard J, Newton AC. PHLiPPing the switch on Akt and protein kinase C signaling. Trends in Endocrinology and Metabolism: Tem. 19: 223-30. PMID 18511290 DOI: 10.1016/J.Tem.2008.04.001 |
0.711 |
|
| 2008 |
Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. The Journal of Biological Chemistry. 283: 6300-11. PMID 18162466 DOI: 10.1074/Jbc.M707319200 |
0.758 |
|
| 2007 |
Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Molecular Cell. 25: 917-31. PMID 17386267 DOI: 10.1016/J.Molcel.2007.02.017 |
0.763 |
|
| 2007 |
Brognard J, Sierecki E, Gao T, Newton AC. Akt Signaling is Differentially Terminated by the Phosphatase PHLPP and a New Isoform, PHLPP2 The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A619 |
0.688 |
|
| 2005 |
Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis. 26: 1182-95. PMID 15790591 DOI: 10.1093/Carcin/Bgi072 |
0.374 |
|
| 2004 |
Brumbaugh KM, Otterness DM, Geisen C, Oliveira V, Brognard J, Li X, Lejeune F, Tibbetts RS, Maquat LE, Abraham RT. The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells Molecular Cell. 14: 585-598. PMID 15175154 DOI: 10.1016/J.Molcel.2004.05.005 |
0.504 |
|
| 2004 |
West KA, Linnoila IR, Brognard J, Belinsky S, Harris C, Dennis PA. Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest. 125: 101S-2S. PMID 15136436 DOI: 10.1378/Chest.125.5_Suppl.101S |
0.337 |
|
| 2004 |
Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA, Li M, Jung M, West KA, Gills JG, Kozikowski AP, Dennis PA. Preferential Inhibition of Akt and Killing of Akt-Dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues Cancer Research. 64: 2782-2792. PMID 15087394 DOI: 10.1158/0008-5472.Can-03-1530 |
0.568 |
|
| 2003 |
Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt Journal of the American Chemical Society. 125: 1144-1145. PMID 12553797 DOI: 10.1021/Ja0285159 |
0.538 |
|
| 2003 |
West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. The Journal of Clinical Investigation. 111: 81-90. PMID 12511591 DOI: 10.1172/Jci16147 |
0.403 |
|
| 2003 |
Brognard J, Dennis PA. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death and Differentiation. 9: 893-904. PMID 12181740 DOI: 10.1038/Sj.Cdd.4401054 |
0.489 |
|
| 2003 |
West KA, Linnoila IR, Brognard J, Belinsky S, Harris CC, Dennis PA. P-326 Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo Lung Cancer. 41. DOI: 10.1016/S0169-5002(03)92294-X |
0.324 |
|
| Show low-probability matches. |